BeStock  
Stocks › Biotechnology › NAMS

NewAmsterdam Pharma NAMS

US equityMarket cap rank #2621Biotechnology
$18.41 −$1.10 (-5.64%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $18.32 -0.49%
Open$19.21
Prev close$19.51
Day range$18.29 – $19.78
Volume1.75M
Market cap$2.21B
P/E (TTM)–
Dividend yield–

NAMS Stock News

Headlines matching NewAmsterdam Pharma or the NAMS ticker, most recent first.

  • Stifel Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $50Market news · 8 Sep 2026 · Direct mention
  • Truist Financial Maintains NewAmsterdam Pharma(NAMS.US) With Buy RatingMarket news · 8 Sep 2026 · Direct mention
  • H.C. Wainwright Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $52Market news · 30 Sep 2026 · Direct mention
  • BMO Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $58Market news · 22 Sep 2026 · Direct mention
  • Truist Financial Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Announces Target Price $57Market news · 22 Sep 2026 · Direct mention
  • William Blair Maintains NewAmsterdam Pharma(NAMS.US) With Buy RatingMarket news · 18 Sep 2026 · Direct mention
  • Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $48Market news · 8 Aug 2026 · Direct mention
  • A Quick Look at Today's Ratings for NewAmsterdam Pharma(NAMS.US), With a Forecast Between $50 to $52Market news · 7 Aug 2026 · Direct mention
  • A Quick Look at Today's Ratings for NewAmsterdam Pharma(NAMS.US), With a Forecast Between $50 to $58Market news · 6 Aug 2026 · Direct mention
  • Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $60Market news · 4 Aug 2026 · Direct mention
  • BMO Capital Initiates NewAmsterdam Pharma(NAMS.US) With Buy Rating, Announces Target Price $58Market news · 21 Jul 2026 · Direct mention
  • RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $51 PositiveMarket news · 30 Jun 2026 · Direct mention
  • Guggenheim Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $45Market news · 8 May 2026 · Direct mention
  • A Quick Look at Today's Ratings for NewAmsterdam Pharma(NAMS.US), With a Forecast Between $45 to $48Market news · 8 May 2026 · Direct mention
  • H.C. Wainwright Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)TipRanks · 8 May 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on NAMS.

Sign in to join the discussion.

Scroll to Top